TRIMAGE: A dedicated trimodality (PET/MR/EEG) imaging tool for schizophrenia.
-
Del Guerra A
Dipartimento di Fisica "E. Fermi", Università di Pisa, Italy; INFN, Sezione di Pisa, Pisa, Italy. Electronic address: alberto.del.guerra@unipi.it.
-
Ahmad S
Weeroc s.a.s., Palaiseau, France.
-
Avram M
Nuklearmedinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Neuroimaging Center (TUM-NIC), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
-
Belcari N
Dipartimento di Fisica "E. Fermi", Università di Pisa, Italy; INFN, Sezione di Pisa, Pisa, Italy.
-
Berneking A
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany.
-
Biagi L
IRCSS, Stella Maris, Calambrone, Pisa, Italy.
-
Bisogni MG
Dipartimento di Fisica "E. Fermi", Università di Pisa, Italy; INFN, Sezione di Pisa, Pisa, Italy.
-
Brandl F
Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Neuroimaging Center (TUM-NIC), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
-
Cabello J
Nuklearmedinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
-
Camarlinghi N
Dipartimento di Fisica "E. Fermi", Università di Pisa, Italy; INFN, Sezione di Pisa, Pisa, Italy.
-
Cerello P
Istituto Nazionale di Fisica Nucleare, Sezione di Torino, Torino, Italy.
-
Choi CH
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany.
-
Coli S
Istituto Nazionale di Fisica Nucleare, Sezione di Torino, Torino, Italy.
-
Colpo S
Advansid s.r.l., Povo, Trento, Italy.
-
Fleury J
Weeroc s.a.s., Palaiseau, France.
-
Gagliardi V
Dipartimento di Fisica "E. Fermi", Università di Pisa, Italy; INFN, Sezione di Pisa, Pisa, Italy.
-
Giraudo G
Istituto Nazionale di Fisica Nucleare, Sezione di Torino, Torino, Italy.
-
Heekeren K
Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, University of Zurich, Switzerland.
-
Kawohl W
Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, University of Zurich, Switzerland; Department of Psychiatry and Psychotherapy, Psychiatric Services of Aargovia, Switzerland.
-
Kostou T
Technological Educational Institute of Athens, Greece.
-
Lefaucheur JL
Inviscan s.a.s., France.
-
Lerche C
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany.
-
Loudos G
Technological Educational Institute of Athens, Greece.
-
Morrocchi M
Dipartimento di Fisica "E. Fermi", Università di Pisa, Italy; INFN, Sezione di Pisa, Pisa, Italy.
-
Muller J
RS2D s.a.s., Mundolsheim, France.
-
Mustafa M
Nuklearmedinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
-
Neuner I
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, JARA Brain, Aachen, Germany.
-
Papadimitroulas P
Technological Educational Institute of Athens, Greece.
-
Pennazio F
Istituto Nazionale di Fisica Nucleare, Sezione di Torino, Torino, Italy.
-
Rajkumar R
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, JARA Brain, Aachen, Germany.
-
Brambilla CR
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany.
-
Rivoire J
RS2D s.a.s., Mundolsheim, France.
-
Kops ER
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany.
-
Scheins J
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany.
-
Schimpf R
RS2D s.a.s., Mundolsheim, France.
-
Shah NJ
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM4, Jülich, Germany.
-
Sorg C
Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Neuroimaging Center (TUM-NIC), Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Department of Psychiatry, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
-
Sportelli G
Dipartimento di Fisica "E. Fermi", Università di Pisa, Italy; INFN, Sezione di Pisa, Pisa, Italy.
-
Tosetti M
IRCSS, Stella Maris, Calambrone, Pisa, Italy.
-
Trinchero R
Istituto Nazionale di Fisica Nucleare, Sezione di Torino, Torino, Italy.
-
Wyss C
Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, University of Zurich, Switzerland.
-
Ziegler S
Nuklearmedinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Department of Nuclear Medicine, University Hospital, LMU, Munich, Germany.
Show more…
Published in:
- European psychiatry : the journal of the Association of European Psychiatrists. - 2018
English
Simultaneous PET/MR/EEG (Positron Emission Tomography - Magnetic Resonance - Electroencephalography), a new tool for the investigation of neuronal networks in the human brain, is presented here within the framework of the European Union Project TRIMAGE. The trimodal, cost-effective PET/MR/EEG imaging tool makes use of cutting edge technology both in PET and in MR fields. A novel type of magnet (1.5T, non-cryogenic) has been built together with a PET scanner that makes use of the most advanced photodetectors (i.e., SiPM matrices), scintillators matrices (LYSO) and digital electronics. The combined PET/MR/EEG system is dedicated to brain imaging and has an inner diameter of 260 mm and an axial Field-of-View of 160 mm. It enables the acquisition and assessment of molecular metabolic information with high spatial and temporal resolution in a given brain simultaneously. The dopaminergic system and the glutamatergic system in schizophrenic patients are investigated via PET, the same physiological/pathophysiological conditions with regard to functional connectivity, via fMRI, and its electrophysiological signature via EEG. In addition to basic neuroscience questions addressing neurovascular-metabolic coupling, this new methodology lays the foundation for individual physiological and pathological fingerprints for a wide research field addressing healthy aging, gender effects, plasticity and different psychiatric and neurological diseases. The preliminary performances of two components of the imaging tool (PET and MR) are discussed. Initial results of the search of possible candidates for suitable schizophrenia biomarkers are also presented as obtained with PET/MR systems available to the collaboration.
-
Language
-
-
Open access status
-
green
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/21809
Statistics
Document views: 15
File downloads: